Growth Factor Gene Therapy for Alzheimer's Disease

Area of Science:

• Neuroscience
• Genetics
• Neurodegenerative Diseases

Background:

• Nervous system growth factors, like brain-derived neurotrophic factor (BDNF), are crucial for neuronal survival and function.
• In Alzheimer's disease (AD) animal models, BDNF demonstrates neuroprotective effects, enhances synaptic plasticity, and improves cognitive function.
• Previous NGF gene therapy trials in AD patients confirmed growth factors can elicit trophic responses in degenerating neurons.

Purpose of the Study:

• To evaluate the efficacy of gene delivery of BDNF in slowing Alzheimer's disease progression.
• To determine if BDNF gene therapy can improve memory and cognitive function in AD patients.

Main Methods:

• Gene delivery of BDNF is being administered to patients diagnosed with Alzheimer's disease.
• Clinical trial NCT05040217 (initiated June 2021) is currently underway.
• Leveraging experience from a prior nerve growth factor (NGF) gene therapy trial (NCT00017940, June 2001) to optimize BDNF delivery.

Main Results:

• The abstract does not contain specific results from the current trial, as it is ongoing.
• Previous NGF gene therapy trial indicated that growth factors can stimulate neuronal repair in AD.

Conclusions:

• Gene delivery of BDNF holds promise as a therapeutic strategy for Alzheimer's disease.
• Optimizing gene delivery methods is key to maximizing the therapeutic potential of growth factors in neurodegenerative conditions.